Fig. 2From: The long-term survival of patients with III-IVb stage nasopharyngeal carcinoma treated with IMRT with or without Nimotuzumab: a propensity score-matched analysisKaplan-Meier plots of distant metastasis-free survival, locoregional relapse–free survival, progression-free survival, and overall survival of NPC patients treated with (green lines) or without Nimotuzumab (blue lines) according the clinical stageBack to article page